FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Aklog Lishan 		2. Issuer Name and Ticker or Trading Symbol

PAVmed Inc. [ PAVM ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chairman and CEO
(Last)          (First)          (Middle)

ONE GRAND CENTRAL PLACE, SUITE 4600 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/12/2018
(Street)

NEW YORK, NY 10165
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                  588413   D  
 
Common Stock   6/12/2018     X    1018   A   (1) 2303   I   By daughter  
Common Stock   6/12/2018     X    980   A   (1) 2280   I   By son  
Common Stock                  4456570   I   By Pavilion Venture Partners LLC   (2)
Common Stock                  20000   I   By HCFP/AG LLC   (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series Z Warrants   $1.60   4/20/2018     G     V    12450    4/5/2018   4/30/2024   Common Stock   12450   $0   363313   (4) D  
 
Subscription Rights (Right to Buy)   $1.15   6/12/2018     X         1018    5/23/2018   6/12/2018   Units (1 share of Common Stock and 1 Series Z Warrant)   1018   $0   0   I   By daughter  
Series Z Warrants   $1.60   6/12/2018     X      1018       4/5/2018   4/30/2024   Common Stock   1018     (1) 1018   I   By daughter  
Subscription Rights (Right to Buy)   $1.15   6/12/2018     X         980    5/23/2018   6/12/2018   Units (1 share of Common Stock and 1 Series Z Warrant)   980   $0   0   I   By son  
Series Z Warrants   $1.60   6/12/2018     X      980       4/5/2018   4/30/2024   Common Stock   980     (1) 980   I   By son  
Series Z Warrants   $1.60   6/26/2018     J      968019       4/5/2018   4/30/2024   Common Stock   2078285     (5) 2078285   I   By Pavilion Venture Partners LLC   (2)
Series Z Warrants   $1.60                    4/5/2018   4/30/2024   Common Stock   10000     10000   I   By HCFP/AG LLC   (3)

Explanation of Responses:
(1)  The reporting person purchased units from the issuer in the issuer's equity rights offering, each unit consisting of one share of the issuer's common stock and one Series Z Warrant, at a price of $1.15 per unit.
(2)  Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and has sole voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his proportionate pecuniary interest therein.
(3)  Dr. Aklog is a co-manager of HCFP/AG LLC, and shares joint voting and dispositive power over the securities held by this entity. Dr. Aklog disclaims beneficial ownership of securities held by this entity, except to the extent of his pecuniary interest therein.
(4)  Reflects 350,538 Series Z Warrants that previously were held indirectly by Dr. Aklog through HCFP/Capital Partners III LLC, and became held directly by Dr. Aklog on June 26, 2018.
(5)  The Series Z Warrants were contributed to such entity by its members for no consideration. The contributed Series Z Warrants include 322,673 Series Z Warrants that were previously held indirectly by Dr. Aklog through HCFP/Capital Partners III LLC and became held directly by Dr. Aklog on June 26, 2016.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Aklog Lishan
ONE GRAND CENTRAL PLACE
SUITE 4600
NEW YORK, NY 10165 		X X Chairman and CEO
Pavilion Venture Partners LLC
ONE GRAND CENTRAL PLACE
SUITE 4600
NEW YORK, NY 10165
X


Signatures
/s/ Dr. Lishan Aklog 7/11/2018
** Signature of Reporting Person Date

/s/ Dr. Lishan Aklog, as manager of Pavilion Venture Partners LLC 7/11/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more PAVmed Charts.
PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more PAVmed Charts.